Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Disease-modifying antirheumatic drug Stories

2012-06-07 11:58:43

Results of a separate study demonstrate that early and sustained remission are associated with decrease mortality According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs). The study also...

2012-06-07 11:56:18

Results of a systematic review urge prophylactic treatment for those at risk Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumor necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism. "Anti-TNFs, such as...

2012-06-07 11:54:21

For every additional 6 months of treatment CV risk reduces further Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumor necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid...

2012-06-01 08:59:44

Education is key to success; functional disability negatively impacts job performance As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood. Arthritis is...

2012-05-14 02:27:41

PARIS, May 14, 2012 /PRNewswire/ -- - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] (NYSE: BMY) today announced that the company will present 18 abstracts on abatacept at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin,...

2012-04-10 10:23:53

NORWALK, Conn., April 10, 2012 /PRNewswire/ -- UBM Medica today announced that Musculoskeletal Network, an online resource for unique and efficient updates on management of musculoskeletal disorders, is following up on its coverage of newly released American College of Rheumatology (ACR) clinical recommendations for rheumatoid arthritis (RA) with concise interviews of lead investigators. The latest ACR recommendations for managing RA include standardized disease activity measures...

2012-04-03 10:06:28

The American College of Rheumatology (ACR) has released the 2012 recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA). The guidelines published today in the ACR journal, Arthritis Care & Research, are an update to the 2008 recommendations and address the issues of initiating and switching drugs, screening for tuberculosis (TB) reactivation, immunization, and the use of biologics in high-risk RA...

2012-02-22 06:00:00

BRUSSELS, Feb. 22, 2012 /PRNewswire/ -- UCB today announced the start of C-EARLY(TM) - a phase III study that will evaluate the efficacy and safety of Cimzia® (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with early, progressive, active, moderate to severe rheumatoid arthritis (RA), who have not previously been treated with disease-modifying antirheumatic drugs (DMARDs). The study also aims to assess whether the...

2011-11-07 13:07:24

Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept, one-third achieved an excellent response, and this response was associated with low measures of disability at study entry, younger age at the onset of JIA, and fewer disease-modifying antirheumatic drugs used before initiating etanercept, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American College of...

2011-11-07 01:00:00

BRUSSELS and CHICAGO, Nov. 7, 2011 /PRNewswire/ -- UCB today announced new data which showed that treatment with Cimzia® (certolizumab pegol) was associated with a rapid and sustained clinical response over 28 weeks in a broad population of moderate to severe rheumatoid arthritis (RA) patients. The results, presented during the American College of Rheumatology's (ACR) 2011 Annual Scientific Meeting in Chicago, November 5-9, are from an open-label extension of the...